AccuStem Sciences
AccuStem Sciences Inc. (OTCQB: ACUT) is a clinical-stage genomics diagnostics company developing novel cancer biomarker tests to improve patient outcomes in oncology. According to accustem.com, the company's platform is built around micro-RNA and multi-gene assays designed for cancer detection and prognostics.
AccuStem's pipeline includes the MSC test — a 24-micro-RNA assay for evaluating lung nodules — and StemPrintER, a 20-gene prognostic assay predicting distant recurrence risk in breast cancer patients. A partnership with EmeritusDX expands the company's blood-based cancer testing capabilities.
Based in New York and London, AccuStem is advancing its diagnostic pipeline through clinical validation and regulatory development. Full pipeline and investor information is available at accustem.com.